Leonid Timashev
Stock Analyst at RBC Capital
(3.46)
# 797
Out of 4,666 analysts
54
Total ratings
48.94%
Success rate
5.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Leonid Timashev
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BHVN Biohaven | Maintains: Outperform | $68 → $66 | $46.83 | +40.94% | 7 | Nov 13, 2024 | |
| CYTK Cytokinetics | Initiates: Outperform | $80 | $49.86 | +60.45% | 1 | Nov 8, 2024 | |
| CMPS COMPASS Pathways | Maintains: Outperform | $23 → $18 | $4.66 | +286.27% | 3 | Nov 1, 2024 | |
| LEGN Legend Biotech | Reiterates: Outperform | $86 | $40.14 | +114.25% | 11 | Oct 29, 2024 | |
| AXSM Axsome Therapeutics | Maintains: Outperform | $130 → $131 | $94.60 | +38.48% | 7 | Oct 4, 2024 | |
| EWTX Edgewise Therapeutics | Maintains: Outperform | $32 → $42 | $31.95 | +31.46% | 9 | Sep 20, 2024 | |
| PYXS Pyxis Oncology | Reiterates: Outperform | $7 | $3.82 | +83.25% | 3 | Sep 19, 2024 | |
| NAMS NewAmsterdam Pharma Company | Reiterates: Outperform | $31 | $20.01 | +54.92% | 5 | Sep 5, 2024 | |
| DSGN Design Therapeutics | Reiterates: Sector Perform | $4 | $5.48 | -27.01% | 8 | Aug 6, 2024 |
Biohaven
Nov 13, 2024
Maintains: Outperform
Price Target: $68 → $66
Current: $46.83
Upside: +40.94%
Cytokinetics
Nov 8, 2024
Initiates: Outperform
Price Target: $80
Current: $49.86
Upside: +60.45%
COMPASS Pathways
Nov 1, 2024
Maintains: Outperform
Price Target: $23 → $18
Current: $4.66
Upside: +286.27%
Legend Biotech
Oct 29, 2024
Reiterates: Outperform
Price Target: $86
Current: $40.14
Upside: +114.25%
Axsome Therapeutics
Oct 4, 2024
Maintains: Outperform
Price Target: $130 → $131
Current: $94.60
Upside: +38.48%
Edgewise Therapeutics
Sep 20, 2024
Maintains: Outperform
Price Target: $32 → $42
Current: $31.95
Upside: +31.46%
Pyxis Oncology
Sep 19, 2024
Reiterates: Outperform
Price Target: $7
Current: $3.82
Upside: +83.25%
NewAmsterdam Pharma Company
Sep 5, 2024
Reiterates: Outperform
Price Target: $31
Current: $20.01
Upside: +54.92%
Design Therapeutics
Aug 6, 2024
Reiterates: Sector Perform
Price Target: $4
Current: $5.48
Upside: -27.01%